Biocon Receives European Commission Marketing Authorization for Pertuzumab Biosimilar Pebrilzo
Biocon Ltd 路 Press Release 路 18 Nov 2026, 2:03 pm
Biocon Receives European Commission Marketing Authorization for Pertuzumab Biosimilar Pebrilzo Biocon Limited announced that the European Commission granted marketing authorization for Pebrilzo, its biosimilar pertuzumab, to treat HER2-positive breast cancer across multiple disease stages in the EU. Pebrilzo is the first biosimilar approved under the European Medicines Agency's new tailored clinical approach, following a positive CHMP opinion on 17th Sep'26 and recent US FDA approval. With this regulatory clearance, pertuzumab becomes Biocon's fifth oncology biosimilar approved in both Europe and the United States, expanding its global biosimilar portfolio.
Original exchange filing (PDF)
More announcements from Biocon Ltd
- Press Release 路 16 Nov 2026
- Intimation on Schedule of Meetings with Analyst(s)/institutional Investor(s) 路 12 Nov 2026
- Earnings Call Transcript for Q2 FY27 路 12 Nov 2026
- Audio and Video Recording of Q2 FY27 Earnings Call 路 05 Nov 2026
- Communication regarding withholding of final dividend for the FY 2025-26 路 04 Nov 2026
- Investor Presentation 路 04 Nov 2026
- Change in Senior Management Personnel 路 04 Nov 2026
- Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on November 04, 2026. 路 04 Nov 2026
